Heritage Investors Management Corp Sells 3,322 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Heritage Investors Management Corp reduced its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 2.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 151,614 shares of the medical equipment provider's stock after selling 3,322 shares during the period. Heritage Investors Management Corp owned 0.08% of Zimmer Biomet worth $16,015,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock worth $524,942,000 after acquiring an additional 125,852 shares during the period. Van ECK Associates Corp grew its holdings in Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after acquiring an additional 218,688 shares during the period. Hotchkis & Wiley Capital Management LLC grew its holdings in Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider's stock worth $189,161,000 after acquiring an additional 577,320 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Zimmer Biomet by 0.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,006,217 shares of the medical equipment provider's stock worth $108,621,000 after acquiring an additional 4,388 shares during the period. Finally, FMR LLC grew its holdings in Zimmer Biomet by 27.6% during the 3rd quarter. FMR LLC now owns 750,336 shares of the medical equipment provider's stock worth $80,999,000 after acquiring an additional 162,384 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock traded up $0.27 during mid-day trading on Friday, hitting $104.32. 2,813,620 shares of the stock were exchanged, compared to its average volume of 1,900,642. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90. The company has a 50-day simple moving average of $105.72 and a 200 day simple moving average of $107.37. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The company has a market capitalization of $20.77 billion, a P/E ratio of 23.44, a P/E/G ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the company posted $2.20 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. Zimmer Biomet's dividend payout ratio is currently 21.57%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ZBH shares. JMP Securities reiterated a "market outperform" rating and set a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Raymond James cut their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Finally, Truist Financial reissued a "hold" rating and set a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of "Hold" and a consensus target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.